Finally, due to the in-trial crossover in the ALTA-1L study comparing the efficacy and safety of brigatinib with crizotinib in patients with advanced ALK-positive NSCLC (11), the OS benefit associated with brigatinib may be underestimated. This evidence concerns the gene ALK and non-small cell lung carcinoma.